Chemomab Therapeutics (CMMB) Return on Capital Employed (2019 - 2025)
Chemomab Therapeutics (CMMB) posted Return on Capital Employed of 8636860.89% for Q4 2025, up 142.98% on a QoQ basis from 3554495.55% in Q3 2025, and up 623630451.0% year-over-year from N/an in Q4 2024.
Chemomab Therapeutics (CMMB) Return on Capital Employed (2019 - 2025) Analysis & Trends
Chemomab Therapeutics' Return on Capital Employed history runs 7 years deep, the most recent figure standing at 8636860.89% for Q4 2025.
- Quarterly Return on Capital Employed rose 623630451.0% year-over-year to 8636860.89% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 8636860.89% (up 623630451.0% YoY) and the FY2025 annual result came in at 293.77%, up 10849.0% from the prior year.
- Return on Capital Employed was 8636860.89% for Q4 2025 at Chemomab Therapeutics, up from 3554495.55% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 8636860.89% in Q4 2025 and bottomed at 35.91% in Q1 2021.
- A 5-year average of 810819.82% and a median of 261.7% in 2023 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed jumped 6998 bps — and 2025, when it soared 623630451 bps.
- Chemomab Therapeutics' Return on Capital Employed stood at 37.24% in 2021, then jumped by 298 bps to 148.32% in 2022, then soared by 154 bps to 377.19% in 2023, then jumped by 636335 bps to 2400556.38% in 2024, then soared by 260 bps to 8636860.89% in 2025.
- Business Quant data shows CMMB's Return on Capital Employed at 8636860.89% in Q4 2025, 3554495.55% in Q3 2025, and 2400556.38% in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Chemomab Therapeutics | 704.11 Mn | 693.75 Mn | - | 8,636,860.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,636,860.89% |
| Sep 30, 2025 | 3,554,495.55% |
| Dec 31, 2024 | 2,400,556.38% |
| Sep 30, 2024 | 432.79% |
| Jun 30, 2024 | 488.98% |
| Mar 31, 2024 | 400.64% |
| Dec 31, 2023 | 377.19% |
| Sep 30, 2023 | 338.39% |
| Jun 30, 2023 | 295.57% |
| Mar 31, 2023 | 227.84% |
| Dec 31, 2022 | 148.32% |
| Sep 30, 2022 | 85.12% |
| Jun 30, 2022 | 54.64% |
| Mar 31, 2022 | 34.08% |
| Dec 31, 2021 | 37.24% |
| Sep 30, 2021 | -20.16% |
| Jun 30, 2021 | -20.68% |
| Mar 31, 2021 | -35.91% |
| Dec 31, 2020 | -129.61% |
| Sep 30, 2020 | -1,044.06% |